In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Latest From Premacure AB

Does Shire Have The Strategy To Deliver On Rare Opportunity In Early/Mid Pipeline?

The biotech laid out its pipeline during a Dec. 10 R&D day in hopes of convincing analysts and investors that its rare disease focus will pay off in coming years.

BioPharmaceutical Research and Development Strategies

Shire Course Corrects Lifitegrast And Eyes Ophthalmology Prospects

The specialty pharma has worked with regulators to determine a next step for its late-stage eye drug and intends to build a business unit around the compound.

BioPharmaceutical North America

Spurring Innovation While Economizing On R&D Spending Remains Industry-Wide Challenge

Cash is still “cheap” but biopharma M&A continues to move slowly – mid-cap industry execs tell “The Pink Sheet” partly because there is so much competition to acquire the best assets. Meanwhile, most companies are economizing on R&D even as they strive to develop the products that will carry them into the next decade.

BioPharmaceutical United States

Shire to pay $4.2bn for rare disease firm ViroPharma

Shire has agreed to pay $4.2bn to acquire ViroPharma, which sells the orphan drug Cinryze. The prophylactic treatment is for the rare disease hereditary angioedema (HAE).

Infectious Diseases Deals
See All

Company Information